Survival Data Support Tarceva Pricing Premium Over Iressa – Genentech/OSI
This article was originally published in The Pink Sheet Daily
Executive Summary
The Tarceva 25% price premium over AstraZeneca's Iressa is justified based upon survival data, Genentech and OSI said during conference calls announcing the oncologic's approval